X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5386) 5386
female (4175) 4175
oncology (3808) 3808
middle aged (3222) 3222
antineoplastic combined chemotherapy protocols - therapeutic use (3128) 3128
chemotherapy (3019) 3019
adult (2733) 2733
aged (2673) 2673
doxorubicin (2639) 2639
male (2378) 2378
doxorubicin - administration & dosage (2376) 2376
cyclophosphamide - administration & dosage (2039) 2039
cancer (1907) 1907
treatment outcome (1777) 1777
cyclophosphamide (1737) 1737
breast neoplasms - drug therapy (1413) 1413
vincristine - administration & dosage (1335) 1335
antineoplastic combined chemotherapy protocols - administration & dosage (1313) 1313
breast cancer (1300) 1300
hematology (1296) 1296
prognosis (1219) 1219
antineoplastic combined chemotherapy protocols - adverse effects (1197) 1197
doxorubicin - therapeutic use (1071) 1071
disease-free survival (1056) 1056
therapy (1056) 1056
rituximab (985) 985
care and treatment (965) 965
medicine & public health (942) 942
prednisone - administration & dosage (913) 913
anthracyclines (883) 883
aged, 80 and over (874) 874
cyclophosphamide - therapeutic use (859) 859
neoplasm staging (849) 849
survival (835) 835
breast neoplasms - pathology (786) 786
retrospective studies (770) 770
lymphomas (765) 765
paclitaxel (748) 748
doxorubicin - adverse effects (732) 732
survival analysis (724) 724
vincristine (720) 720
lymphoma, large b-cell, diffuse - drug therapy (716) 716
combined modality therapy (709) 709
adolescent (703) 703
vincristine - therapeutic use (700) 700
survival rate (668) 668
antineoplastic agents - therapeutic use (654) 654
trial (606) 606
research (590) 590
docetaxel (588) 588
drug administration schedule (588) 588
non-hodgkins-lymphoma (581) 581
cyclophosphamide - adverse effects (571) 571
prednisone - therapeutic use (562) 562
follow-up studies (559) 559
drug therapy (550) 550
analysis (525) 525
chemotherapy, adjuvant (523) 523
young adult (516) 516
cisplatin (472) 472
risk factors (450) 450
pharmacology & pharmacy (445) 445
clinical trials (444) 444
health aspects (444) 444
elderly-patients (440) 440
prednisone (431) 431
cisplatin - administration & dosage (429) 429
tumors (426) 426
combination (421) 421
patients (419) 419
animals (416) 416
remission induction (411) 411
trastuzumab (407) 407
paclitaxel - administration & dosage (406) 406
etoposide - administration & dosage (402) 402
prospective studies (400) 400
lymphoma (397) 397
adjuvant chemotherapy (392) 392
toxicity (387) 387
phase-ii (384) 384
vincristine - adverse effects (379) 379
pegylated liposomal doxorubicin (377) 377
cancer therapies (375) 375
antibodies, monoclonal, murine-derived (366) 366
carcinoma (362) 362
expression (357) 357
hematology, oncology and palliative medicine (356) 356
time factors (354) 354
radiotherapy (350) 350
lymphoma, large b-cell, diffuse - pathology (346) 346
methotrexate - administration & dosage (343) 343
neoadjuvant therapy (343) 343
fluorouracil - administration & dosage (339) 339
antineoplastic agents - adverse effects (337) 337
antineoplastic agents - administration & dosage (336) 336
b-cell lymphoma (332) 332
transplantation (332) 332
antibodies, monoclonal, murine-derived - administration & dosage (330) 330
kaplan-meier estimate (330) 330
surgery (329) 329
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6169) 6169
Japanese (63) 63
Chinese (30) 30
French (18) 18
German (15) 15
Russian (11) 11
Spanish (11) 11
Italian (8) 8
Portuguese (3) 3
Polish (2) 2
Korean (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Lancet (British edition), ISSN 0140-6736, 2013, Volume 381, Issue 9873, pp. 1203 - 1210
Summary Background Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone... 
Internal Medicine | SURVIVAL | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | II MULTICENTER | B-CELL | ADVANCED FOLLICULAR LYMPHOMA | CYCLOPHOSPHAMIDE | VINCRISTINE | NON-HODGKINS-LYMPHOMA | COMBINATION | CHEMOTHERAPY | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prospective Studies | Nitrogen Mustard Compounds - administration & dosage | Humans | Middle Aged | Antibodies, Monoclonal, Murine-Derived - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cyclophosphamide - adverse effects | Vincristine - administration & dosage | Adult | Doxorubicin - administration & dosage | Prednisone - administration & dosage | Prednisone - adverse effects | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Nitrogen Mustard Compounds - adverse effects | Disease-Free Survival | Bendamustine Hydrochloride | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Vincristine - adverse effects | Aged | Infusions, Intravenous | Antibodies, Monoclonal, Murine-Derived - adverse effects | Doxorubicin - adverse effects | Usage | Chemotherapy | Bendamustine | Patient outcomes | Lymphomas | Research | Drug therapy | Comparative analysis | Cancer | Antimitotic agents | Care and treatment | Antineoplastic agents | Analysis | Bone marrow | Hematology
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 31, pp. 3792 - 3799
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2019, Volume 37, Issue 15, pp. 1285 - 1295
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 23, pp. 2516 - 2522
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2010, Volume 28, Issue 9, pp. 1473 - 1480
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2012, Volume 30, Issue 28, pp. 3452 - 3459
Journal Article
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1121 - 1128
Journal Article
Journal Article
Journal Article